IJBTT

Computer-aided and Herbal Informatics based Drug Designing for Potential Lung Cancer Therapeutics

	International Journal of Biotech Trends and Technology (IJBTT)
	© 2021 by IJBTT Journal
	Volume - 11 Issue - 3
	Year of Publication : 2021
	Authors : Debanjoy Paul, Preeti Pannu, Madhavi Sinha, Vaishali Bisht
	DOI :  10.14445/22490183/IJBTT-V11I3P602

Citation

MLA Style:Debanjoy Paul, Preeti Pannu, Madhavi Sinha, Vaishali Bisht  "Computer-aided and Herbal Informatics based Drug Designing for Potential Lung Cancer Therapeutics" International Journal of Biotech Trends and Technology 11.3 (2021): 8-17.

APA Style:Debanjoy Paul, Preeti Pannu, Madhavi Sinha, Vaishali Bisht(2021). Computer-aided and Herbal Informatics based Drug Designing for Potential Lung Cancer Therapeutics. International Journal of Biotech Trends and Technology, 11(3), 8-17.

Abstract

Lung was very rare at the beginning of the last century, but later according to a cancer statistic report, it becomes the most common cancer worldwide since 1985. But there are still multiple risk factors, including environmental, hormonal, genetic, and viral, that have been implicated in the pathogenesis of lung cancer in never-smokers; no related factor has been there that can explain the high incidence of lung cancer in never-smokers. Drug design describes the search of novel compounds with biological activity on a systematic basis. The drug design process has focused on the molecular determinants of the interactions between the drug and molecular target. It is cost-efficient, time-saving, and the process is automatic. We can also know the drug-receptor interaction pattern. Through searching huge libraries of phytochemicals compounds, it can give high hit rates compounds comparison to other high throughput screening, and there is a little chance of failures in the final phases.

References

[1] Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 Int J Cancer (2010) 127:2893-917.
[2] Ganesh B, Sushama S, Monika S, Suvarna P. A Case-control Study of Risk Factors for Lung Cancer in Mumbai, India. Asian Pac J Cancer Prev (2011) 12:357-62.
[3] Toh CK, Gao F, Lim WT, Leong SS, Fong KW, Yap SP, et al. Never-Smokers With Lung Cancer: Epidemiologic Evidence of a Distinct Disease Entity. J ClinOncol (2006) 24:2245-51.
[4] Gajalakshmi V, Hung RJ, Mathew A, Varghese C, Brennan P, Boffetta P. Tobacco smoking and chewing, alcohol drinking and lung cancer risk among men in southern India. Int J Cancer (2003) 107:441-7.
[5] Gealy R, Zhang L, Siegfried JM, Luketich JD, Keohavong P. Comparison of mutations in the p53 and K-ras genes in lung carcinomas from smoking and nonsmoking women. Cancer Epidemiol Biomarkers Prev (1999) 8:297-302.
[6] Hainaut P, Pfeifer GP. Patterns of p53 G-->T transversions in lung cancers reflect the primary mutagenic signature of DNA damage by tobacco smoke. Carcinogenesis 200; 22:367-74.
[7] Durré T, Morfoisse F, Erpicum C, Ebroin M, Blacher S, García-Caballero M, Deroanne C, Louis T, Balsat C, Van de Velde M, Kaijalainen S, Kridelka F, Engelholm L, Struman I, Alitalo K, Behrendt N, Paupert J, Noel A. uPARAP/Endo180 receptor is a gatekeeper of VEGFR-2/VEGFR-3 heterodimerization during pathological lymphangiogenesis. Nat Commun., 5;9(1) (2018) 5178.
[8] Rapisarda A, Melillo G. Role of the VEGF/VEGFR axis in cancer biology and therapy. Adv Cancer Res., 114 (2012) 237-67.
[9] Durré T, Morfoisse F, Erpicum C, Ebroin M, Blacher S, García-Caballero M, Deroanne C, Louis T, Balsat C, Van de Velde M, Kaijalainen S, Kridelka F, Engelholm L, Struman I, Alitalo K, Behrendt N, Paupert J, Noel A. uPARAP/Endo180 receptor is a gatekeeper of VEGFR-2/VEGFR-3 heterodimerization during pathological lymphangiogenesis. Nat Commun., 5, 9(1) (2018) 5178.
[10] Manuela S Murgueitio , Marcel Bermudez , JérémieMortier , Gerhard Wolber. In silico virtual screening approaches for anti-viral drug discovery 9 (2012) 219-2
[11] Imam SS, Gilani SJ. Computer-Aided Drug Design: A Novel Loom To Drug Discovery. Org. Med. Chem., 1(4) (2017) 1-6.
[12] Anderson AC. The process of structure-based drug design. Chemistry & biology. , 10(9) (2003) 787-97.
[13] Prashant Mathur, DNB, PhD1; Krishnan Sathishkumar, MSc1; MeeshaChaturvedi, MBBS1; Priyanka Das, B-Level1; KondalliLakshminarayanaSudarshan, MSc1; Stephen Santhappan, MSc, MPhil1; VinodhNallasamy, MSc, MPhil1; Anish John, BE1; Sandeep Narasimhan, MSc1; and Francis SelvarajRoselind, MSc1; JCO GLOBAL Oncology no. 6(2020) 1063-1075.
[14] Chayan Acharya, Andrew Coop, James E. Polli, and Alexander D. MacKerell, “Recent Advances in Ligand-Based Drug Design: Relevance and Utility of the Conformationally Sampled Pharmacophore Approach”, Current Computer-Aided Drug Design 7(1) (2011)
[15] FZhang S. Computer-aided drug discovery and development. In Drug Design and Discovery. , (2011) 716:23-38.
[16] Kapetanovic IM. Computer-aided drug discovery and development (CADD): in silicon-chemical-biological approach. Chemical-biological interactions. , 71(2) (2008) 165-76
[17] Duursma AM, Agami R. Ras interference as cancer therapy. Semin Cancer Biol., (2003) 267-73. PMID: 14563121.
[18] Friday BB, Adjei AA. K-ras as a target for cancer therapy. Biochim Biophys Acta., (2005) 1756:127-44. PMID: 16139957.
[19] Imam SS, Gilani SJ. Computer-Aided Drug Design: A Novel Loom To Drug Discovery. Org. Med. Chem., 1(4) (2017) 1-6.
[20] Nagase T, Seki N, Tanaka A, Ishikawa K, Nomura N. Prediction of the coding sequences of unidentified human genes. IV. The coding sequences of 40 new genes (KIAA0121-KIAA0160) were deduced by analysis of cDNA clones from human cell line KG-1. DNA Res. (1995) 2:167-210.
[21] Inoue A, Takahashi KP, Kimura M, Watanabe T, Morisawa S. Molecular cloning of an RNA binding protein, S1?1. Nucleic Acids Res., (1996) 24:2990–2997.
[22] Johnston JJ, Teer JK, Cherukuri PF, et al. Massively parallel sequencing of exons on the X chromosome identifies RBM10 as the gene that causes a syndromic form of cleft palate. Am J Hum Genet., (2010) 86:743–748.
[23] Gorlin RJ, Cervenka J, Anderson RC, Sauk JJ, Bevis WD. Robin`s syndrome. A probably X?linked recessive subvariety exhibiting persistence of left superior vena cava and atrial septal defect. Am J Dis Child., (1970) 119:176–178.
[24] Sebestyen E, Singh B, Minana B, et al. Large?scale analysis of genome and transcriptome alterations in multiple tumors unveils novel cancer?relevant splicing networks. Genome Res. , (2016) 26:732–744.
[25] Lukong KE, Chang KW, Khandjian EW, Richard S. RNA?binding proteins in human genetic disease. Trends Genet. (2008) 24:416–425.
[26] Gripp KW, Hopkins E, Johnston JJ, Krause C, Dobyns WB, Biesecker LG. Long?term survival in TARP syndrome and confirmation of RBM10 as the disease?causing gene. Am J Med Genet A 155A? (10) (2011) 2516–2520.
[27] Powis Z, Hart A, Cherny S, et al. Clinical diagnostic exome evaluation for an infant with a lethal disorder: genetic diagnosis of TARP syndrome and expansion of the phenotype in a patient with a newly reported RBM10 alteration. BMC Med Genet. (2017) 18:60.
[28] Zhong Z, Zhang Q, Tao H, Sang W, Cui L, Qiang W, et al. Anti-inflammatory activities of Sigesbeckiaglabrescens Makino: combined in vitro and in silico investigations. Chin Med. (2019) 14:35.
[29] Kharat, Mahesh, et al. “Physical and Chemical Stability of Curcumin in Aqueous Solutions and Emulsions: Impact of pH, Temperature, and Molecular Environment.” Journal of agricultural and food chemistry 65(8) (2017) 1525-1532.
[30] Okimoto RA, Lin L, Olivas V, et al. Preclinical efficacy of an RAF inhibitor that evades paradoxical MAPK pathway activation in protein kinase BRAF-mutant lung cancer. ProcNatlAcadSci U S A (2016) 113:13456-61.
[31] Amaral T, Sinnberg T, Meier F, et al. MAPK pathway in melanoma part II-secondary and adaptive resistance mechanisms to BRAF inhibition. Eur J Cancer (2017) 73:93-101
[32] Rudin CM, Hong K, Streit M. Molecular characterization of acquired resistance to the BRAF inhibitor dabrafenib in a patient with BRAF-mutant non-small-cell lung cancer. J ThoracOncol (2013) 8:e41-2.
[33] Spagnolo F, Ghiorzo P, Queirolo P. Overcoming resistance to BRAF inhibition in BRAF-mutated metastatic melanoma. Oncotarget (2014) 5:10206-21.
[34] Jain P, Silva A, Han HJ, et al. Overcoming resistance to single-agent therapy for oncogenic BRAF gene fusions via combinatorial targeting of MAPK and PI3K/mTORsignaling pathways. Oncotarget (2017) 8:84697-713.
[35] Marchetti A, Felicioni L, Malatesta S, et al. Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations. J ClinOncol (2011) 29:3574-9.
[36] Paik PK, Arcila ME, Fara M, et al. Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations. J ClinOncol (2011) 29:2046-51.
[37] Cardarella S, Ogino A, Nishino M, et al. Clinical, pathologic, and biologic features associated with BRAF mutations in non-small cell lung cancer. Clin Cancer Res (2013) 19:4532-40.
[38] Ding X, Zhang Z, Jiang T, et al. Clinicopathologic characteristics and outcomes of Chinese patients with non-small-cell lung cancer and BRAF mutation. Cancer Med (2017) 6:555-62.
[39] Sasaki H, Endo K, Okuda K, Kawano O, Kitahara N, Tanaka H, et al. Epidermal growth factor receptor gene amplification and gefitinib sensitivity in patients with recurrent lung cancer. J Cancer Res ClinOncol. (2008)134:469–77.
[40] Gupta R, Dastane AM, Forozan F, Riley-Portuguez A, Chung F, Lopategui J, et al. Evaluation of EGFR abnormalities in patients with pulmonary adenocarcinoma: the need to test neoplasms with more than one method. Mod Pathol. (2009) 22:128–33.
[41] Ladanyi M, Pao W. Lung adenocarcinoma: guiding EGFR-targeted therapy and beyond. Mod Pathol. , (2008) 21:S16–22.
[42] Massarelli E, Varella-Garcia M, Tang X, Xavier AC, Ozburn NC, Liu DD, et al. KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Clin Cancer Res. (2007) 13:2890–6.
[43] Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutation in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. (2004) 350:2129–39.
[44] Balak MN, Gong Y, Riely GJ, Somwar R, Li AR, Zakowski MF, et al. Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. Clin Cancer Res. (2006) 12:6494–501.
[45] Malhotra A., Nair P., Dhawan D.K. Premature mitochondrial senescence and related ultrastructural changes during lung carcinogenesis modulation by curcumin and resveratrol. Ultrastruct. Pathol. , (2012) 36:179–184.
[46] Busquets S., Ametller E., Fuster G., Olivan M., Raab V., Argiles J.M., Lopez-Soriano F.J. Resveratrol, a natural diphenol, reduces metastatic growth in an experimental cancer model. Cancer Lett., (2007)245:144–148.
[47] Tamilselvam Rajavel, KasiPandimaDevi. Phytochemicals as Epigenetic Modifiers for Cancer Management with Special Reference to Lung Cancer., (2019).
[48] S. Biswas, I. Rahman, in Bioactive Food as Dietary Interventions for Liver and Gastrointestinal Disease, (2013).
[49] FZhang S. Computer-aided drug discovery and development. In Drug Design and Discovery. , 716 (2011) 23-38.
[50] Kapetanovic IM. Computer-aided drug discovery and development (CADD): in silicon-chemical-biological approach. Chemical-biological interactions. , 171(2) (2008) 165-76.
[51] Imam SS, Gilani SJ. Computer-Aided Drug Design: A Novel Loom To Drug Discovery. Org. Med. Chem., 1(4) (2017) 1-6.
[52] Anderson AC. The process of structure-based drug design. Chemistry & biology., 10(9) (2003) 787-97.
[53] PrashantMathur, DNB, PhD1; Krishnan Sathishkumar, MSc1; MeeshaChaturvedi, MBBS1; Priyanka Das, B-Level1; KondalliLakshminarayanaSudarshan, MSc1; Stephen Santhappan, MSc, MPhil1; VinodhNallasamy, MSc, MPhil1; Anish John, BE1; Sandeep Narasimhan, MSc1; and Francis SelvarajRoselind, MSc1; JCO GLOBAL Oncology no. 6(2020) 1063-1075.
[54] SampledPharmacophore Approach, Current Computer-Aided Drug Design (2011) 7: Chayan Acharya, Andrew Coop, James E. Polli, and Alexander D. MacKerell, Recent Advances in Ligand-Based Drug Design: Relevance and Utility of the Conformationally
[55] Steinmann J., Buer J., Pietschmann T., Steinmann E. Anti-infective properties of epigallocatechin-3-gallate (EGCG), a component of green tea. Br. J. Pharmacol. (2013) 168:1059–1073. doi: 10.1111/bph.12009.
[56] Chantre P., Lairon D. Recent finding of green tea extract AR25 (Exolise) and its activity for the treatment of obesity. Phytomedicine. (2002) 9:3–8. doi: 10.1078/0944-7113-00078.
[57] Leung L.K., Su Y., Chen R. Theaflavins in black tea and catechins in green tea are equally effective antioxidants. J. Nutr., (2001) 131:2248–2251. doi: 10.1093/jn/131.9.2248.
[58] Zhang C., Suen C.L.C., Yang C., Quek S.Y. Antioxidant capacity and major polyphenol composition of teas as affected by geographical location, plantation elevation, and leaf grade. Food Chem., (2018) 244:109–119. doi: 10.1016/j.foodchem.2017.09.126.
[59] Yanagimoto K., Ochi H., Lee K.G., Shibamoto T. Antioxidative activities of volatile extracts from green tea, oolong tea, and black tea. J. Agric. Food Chem., (2003) 51:7396–7401. doi: 10.1021/jf030127i.
[60] Juneja L.R., Chu D.-C., Okubo T. L-theanine—A unique amino acid of green tea and its relaxation effect in humans. Trends Food Sci. Technol. 1999; 10:199–204. doi: 10.1016/S0924-2244(99)00044-8.
[61] Yoshizawa S., Horiuchi T., Sugimura M. Penta-o-galloyl-?-D-glucose and epigallocatechin gallate: Cancer prevention agent. Phenolic Compounds in Food and Health II. Antioxidant and cancer prevention. Washington DC. Am. Chem. Soc. 1992;2:118–119.
[62] Mazieres J, Cropet C, Montané L, Barlesi F, Souquet PJ, Quantin X, Dubos-Arvis C, Otto J, Favier L, Avrillon V, Cadranel J, Moro-Sibilot D, Monnet I, Westeel V, Le Treut J, Brain E, Trédaniel J, Jaffro M, Collot S, Ferretti GR, Tiffon C, Mahier-Ait Oukhatar C, Blay JY. Vemurafenib in non-small-cell lung cancer patients with BRAFV600 and BRAFnonV600 mutations. Ann Oncol. 2020 Feb;31(2):289-294. doi: 10.1016/j.annonc.2019.10.022. Epub 2020 Jan 3. PMID: 31959346.
[63] Hyman DM, Puzanov I, Subbiah V, Faris JE, Chau I, Blay JY, Wolf J, Raje NS, Diamond EL, Hollebecque A, Gervais R, Elez-Fernandez ME, Italiano A, Hofheinz RD, Hidalgo M, Chan E, Schuler M, Lasserre SF, Makrutzki M, Sirzen F, Veronese ML, Tabernero J, Baselga J. Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations. N Engl J Med. 2015 Aug 20;373(8):726-36. doi: 10.1056/NEJMoa1502309. Erratum in: N Engl J Med. 2018 Oct 18;379(16):1585. PMID: 26287849; PMCID: PMC4971773.
[64] Joshi M, Rice SJ, Liu X, Miller B, Belani CP. Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer. PLoS One. 2015 Feb 23;10(2) e0118210. doi: 10.1371/journal.pone.0118210. PMID: 25706985; PMCID: PMC4338247.
[65] Robinson SD, O`Shaughnessy JA, Cowey CL, Konduri K. BRAF V600E-mutated lung adenocarcinoma with metastases to the brain responding to treatment with vemurafenib. Lung Cancer., 85(2) (2014) 326-30. doi: 10.1016/j.lungcan.2014.05.009. Epub 2014 May 21. PMID: 24888229.
[66] Zubair H, Azim S, Ahmad A, et al. Cancer Chemoprevention by Phytochemicals: Nature`s Healing Touch. Molecules., 22(3) (2017) 395. Published 2017 Mar 3. doi:10.3390/molecules22030395;20(20):4981.
[67] Ranjan A, Ramachandran S, Gupta N, et al. Role of Phytochemicals in Cancer Prevention. Int J Mol Sci., (2019).
[68] Efferth, Thomas, et al., Integration of phytochemicals and phytotherapy into cancer precision medicine., Oncotarget ., 8(30) (2017) 50284-50304. doi:10.18632/oncotarget.17466.
[69] Jones V, Katiyar SK. Emerging phytochemicals for prevention of melanoma invasion. Cancer Lett., 335(2) (2013) 251-258. doi:10.1016/j.canlet.2013.02.056.
[70] Zhang L, Huang Y, Zhuo W, Zhu Y, Zhu B, Chen Z. Fisetin, a dietary phytochemical, overcomes Erlotinib-resistance of lung adenocarcinoma cells through inhibition of MAPK and AKT pathways. Am J Transl Res., 8(11) (2016) 4857-4868. Published 2016o
[71] Chirumbolo S, Bjørklund G, Lysiuk R, Vella A, Lenchyk L, Upyr T. Targeting Cancer with Phytochemicals via Their Fine-Tuning of the Cell Survival Signaling Pathways. Int J Mol Sci., 19(11) (2018) 3568. Published 2Singh S, Sharma B, Kanwar SS, Kumar A. Lead Phytochemicals for Anticancer Drug Development. Front Plant Sci. 2016; 7:1667. Published 2016 Nov 8. doi:10.3389/fpls.2016.01667018 Nov 12
[72] Hosseini A, Ghorbani A. Cancer therapy with phytochemicals: evidence from clinical studies. Avicenna J Phytomed. , 5(2) (2015) 84-97.
[73] Wang H, Khor TO, Shu L et al. Plants vs. cancer: a review on natural phytochemicals in preventing and treating cancers and their druggability. Anticancer Agents Med Chem. 12(10) (2012) 1281-1305. Doi: 10.2174/187152012803833026.
[74] Dr.P.Gopiraman, "Cigarette Smoking Induced Human Cellular Oxidative Deregulations" SSRG International Journal of Applied Chemistry 2.1 (2015): 1-4.

Keywords
Cancer, CADD, Therapeutics, Phytochemicals, and Lung cancer.